

B1
cDNA in some cases); and the sixth column, the percent identity to the human cDNA.

The paragraph beginning at page 14, line 34 has been amended as follows:

B2
The cDNA and fragments and variants thereof (SEQ ID NOs:3-29) may be used in hybridization, amplification, and screening technologies to identify and distinguish among SEQ ID NO:1, SEQ ID NO:2, and related molecules in a sample. The mammalian cDNAs may be used to produce transgenic cell lines or organisms which are model systems for human colon disorders, particularly colon cancer, Crohn's disease, and ulcerative colitis and upon which the toxicity and efficacy of potential therapeutic treatments may be tested. Toxicology studies, clinical trials, and subject/patient treatment profiles may be performed and monitored using the cDNAs, proteins, antibodies and molecules and compounds identified using the cDNAs and proteins of the present invention.
